

Please type a plus sign (+) inside this box →



06-2404

Ifw

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/698,160
		Filing Date	October 30, 2003
		First Named Inventor	YU, DE CHAO
		Group Art Unit	1645
		Examiner Name	
Total Number of Pages in This Submission	5 + refs.	Attorney Docket Number	CELL-023
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08A 2. Cited references 3. Postcard	
<input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/>		
Remarks			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36.677 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	June 17, 2004		

EXPRESS MAIL LABEL NO. EV333997445US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV333997445US

INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	CELL-023
	First Named Inventor	YU, DE CHAO
	Application Number	10/698,160
	Confirmation No.	9850
	Filing Date	October 30, 2003
	Group Art Unit	1645
	Examiner Name	
	Title:	"CELL-SPECIFIC ADENOVIRUS VECTOR COMPRISING EBV-SPECIFIC PROMOTER"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. CELL-023 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: June 17, 2004

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,160
				Filing Date	October 30, 2003
				First Named Inventor	YU, DE-CHAO
				Art Unit	1645
Sheet	1	of	3	Examiner Name	
				Attorney Docket Number	CELL-023

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		20010006633		Julv 5. 2001	KIRN	
		20010053768		December 20. 2001	GREGORY et al.	
		20030026789		February 6. 2003	GREGORY et al.	
		20030068307		April 10. 2003	YU et al.	
		20030104625		June 5. 2003	CHENG et al.	
		20040009588		January 15. 2004	CHANG et al.	
		5.998.205		December 7. 1999	HALLENBECK et	
		6.432.700		August 13. 2002	HENDERSON et	
		6.551.587		April 22. 2003	HALLENBECK et	
		6.638.762		October 28. 2003	CHANG et al.	
		6.692.736		February 17. 2004	YU et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 01/36650	25 May 2001	ONYX		
		WO 01/72341	4 Oct. 2001	CALYDON		
		WO 01/73093	4 Oct. 2001	CALYDON		
		WO 02/067861	6 Sept. 2002	NOVARTIS		
		WO 92/03563	5 Mar. 1992	CENTRAAL		
		WO 96/17053	6 June 1996	GENETIC		
		WO 96/34969	7 Nov. 1996	CANJI		
		WO 98/29555	9 July 1998	ONYX		
		WO 98/39464	11 Sept. 1998	CALYDON		
		WO 99/25860	27 May 1999	NOVARITIS		
		WO 99/59604	25 Nov. 1999	ONYX		
		WO 99/28469	10 June 1999	GENZYME		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 17 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/698,160	
			Filing Date	October 30, 2003	
			First Named Inventor	YU, DE-CHAO	
			Art Unit	1645	
Sheet	2	of	3	Examiner Name	
				Attorney Docket Number	CELL-023
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		CHEN et al., LINKAGE BETWEEN STAT REGULATION AND EPSTEIN-BARR VIRUS GENE EXPRESSION IN TUMORS, J. Virol., 2001, 75(6): 2929-2937			
		CHIA et al., A NOVEL CONDITIONALLY ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA (NPC), Proc. Amer. Ass. For Cancer Res., 2002, 43: 1098-1099			
		CHIOCCA et al., ONCOLYTIC VIRUSES, Nature Publishing Group, 2002, 2: 938-951			
		FENG et al., USE OF ADENOVIRUS VECTORS EXPRESSING EPSTEIN-BARR VIRUS (EBV) IMMEDIATE-EARLY PROTEIN BZLF1 OR BRLF1 TO TREAT EBV-POSITIVE TUMORS, J Virol., 2002, 76(21):10951-10959			
		GRINSTEIN et al., DEMONSTRATION OF EPSTEIN-BARR VIRUS IN CARCINOMAS OF VARIOUS SITES, Cancer Res., 2002, 1:62(17):4876-4878			
		LI et al., TUMOR-TARGETED GENE THERAPY FOR NASOPHARYNGEAL CARCINOMA, Cancer Res., 2002, 62: 171-178			
		REISMAN et al., TRANS ACTIVATION OF AN EPSTEIN-BARR VIRAL TRANSCRIPTIONAL ENHANCER BY THE EPSTEIN-BARR VIRAL NUCLEAR ANTIGEN 1, Molecular and Cell. Biol., 1986, 6(11): 3838-3846			
		SADLER et al., THE EPSTEIN-BARR VIRUS 3.5-KILOBASE LATENT MEMBRANE PROTEIN 1 MRNA INITIATES FROM A TATA-LESS PROMOTER WITHIN THE FIRST TERMINAL REPEAT, J. of Virol., 1995, 69(7): 4577-4581			
		SJÖBLOM et al., AN ATF/CRE ELEMENT MEDIATES BOTH EBNA2-DEPENDENT AND EBNA2-INDEPENDENT ACTIVATION OF THE EPSTEIN-BARR VIRUS LMP1 GENE PROMOTER, J. of Virol., 1998, 72(2): 1365-1376			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 17 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/698,160	
			Filing Date	October 30, 2003	
			First Named Inventor	YU, DE-CHAO	
			Art Unit	1645	
			Examiner Name		
Sheet	3	of	3	Attorney Docket Number	CELL-023
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		TSAI et al., ADDITIVE EFFECT OF SP1 AND SP3 IN REGULATION OF THE ED-1E PROMOTER OF THE EBV LMP 1 GENE IN HUMAN EPITHELIAL CELLS, Virology, 1999, 261: 288-294			
		YU et al., SELECTIVELY REPLICATING ONCOLYTIC ADENOVIRUSES AS CANCER THERAPEUTICS, Curr. Opinion in Mol. Ther., 2002, 4(5): 435-443			
		WAEHLER et al., EXPERIMENTAL GENE THERAPY OF HEPATOCELLULAR CARCINOMA: EXPRESSION OF IL-12, 4-1BBL AND IL-2 FROM A SINGLE ADENOVIRAL VECTOR, 10 TH Annual ESGT meeting, Oct. 13-16, 2002			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

DATE: June 17, 2004



EV333997445US

THE EXPRESS MAIL NUMBER OF THE DAY IS: EV333997445US

The person taking the Express Mail to the Post Office is: Stuart McLeish

EXPRESS MAIL CERTIFICATION

Date of Deposit: **06/17/2004** I hereby certify that the below-listed papers or fees were inserted into a package addressed to: Commissioner for Patents, PO BOX 1450, Alexandria, Virginia 22313-1450 and was deposited by me with the United States Postal Service "Express Mail Post Office Addressee" service under 37 C.F.R. § 1.10 on the date indicated above.

Signature

Date

6/17/04

Atty. Docket No.	Serial Number	Description	Atty.	Fee
LIFE-070DIV	10/663,217	Transmittal, Fee Transmittal <i>in duplicate</i> , IDS, SVB08A, (7) Cited References	SCT	
UCAL-082CON	09/938,853	PTOL-85 <i>in duplicate</i>	KYB	\$1,630
AGYT-041	10/764,292	Transmittal, Fee Transmittal <i>in duplicate</i> , Revocation/POA, Copy of Notice TO file Missing Parts, Executed Declaration	PJS	\$65
UCSF-129CON	10/795,002	Transmittal, IDS, SB08A, (1) Cited Reference	JSK	
UCSF-129DIV	10/794,144	Transmittal, IDS, SB08A, (1) Cited Reference	JSK	
RIGL-013	10/142,648	Restriction Election	JSK	
RIGL-002CON	09/651,150	Amendment	JSK	
LIFE-040	09/988,494	Request for RCE Transmittal, Fee Transmittal <i>in duplicate</i> , Petition for a 1 Month Extension of Time, Executed Declaration, IDS, SB08A, Copy of (1) cited Reference	SCT	\$880
AGYT-035CIP	10/112,667	Transmittal, Request for a 1 Month Extension of Time <i>in duplicate</i> , Amendment, (10) Exhibits Express Mail No. EV333997445US	PJS	\$55
STAN-203CIP	10/779,090	Transmittal, IDS, SB08A, Copies of 1449's & PTO-892's from Parent, (9) Cited References	PAB	
SMAR-018DIV	10/666,005	Transmittal, Certified Copy of CA 2,332,201	BEF	
CELL-023	10/698,160	Transmittal, IDS, SB08A, (24) Cited References	PJS	
LIFE-080CON	10/278,170	Transmittal, Fee Transmittal <i>in duplicate</i> , Terminal Disclaimer, Amendment After Final Rejection	CML	\$110